Cell & Gene Therapy Ltd.
Applying the medicine of the future now
Our Aim
Cell&Gene Therapy Ltd (CGT Ltd) operates across various countries with the purpose of developing new genetic drugs and diagnostic systems.
This is accomplished by attracting specialists and by forming international groups focused at achieving results in concrete projects, stages of research or inconsortiums with other specialized structures, research teams and companies.
Our Vectors
Our Unique Value Proposition
We have refined the non-viral vector approach to address its traditional drawbacks, prioritizing safety and efficiency. Our proprietary vector offers four key innovations:
-
Enhanced Safety: By eliminating antibiotic resistance genes, we minimize potential risks;
-
Viral-Element Free: No viral components are included in the construct, further boosting overall safety;
-
Optimized Vector Design: A smaller vector length ensures more efficient gene delivery;
-
Industrial-Scale Production: The construction is readily scalable, supporting robust and cost-effective manufacturing.
Our Vaccine
We have developed an innovative DNA-based vaccine against SARS-CoV-2, leveraging our proprietary DNA vectors to encode immunogenic epitopes of the virus's proteins.
The following milestones have been achieved:
-
Completed vaccine prototypes;
-
Secured international patent protection;
-
Performed initial in vitro and in vivo studies, confirming the vaccine’s efficacy and safety;
-
Prepared industrial-scale manufacturing processes to ensure competitive pricing
The vaccine is currently available for further development or collaboration opportunities.
